hk2

UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.

SphK2-IN-3 (compound 12q) is a selective sphingosine kinase 2 inhibitor. It exhibits antiproliferative effects on various cancer cells and can induce G2 phase arrest and apoptosis in HepG2 liver cancer cells.

SphK2-IN-2 (21g) is a potent and selective SphK2 inhibitor with an IC50 of 0.23 μM.

SphK2-IN-1 is an SphK2 inhibitor with an IC50 value of 0.359 μM. SphK2-IN-1 can be used to study cancer, inflammation, neurological and cardiovascular diseases.

Chk2-IN-2 (compound 2) serves as a selective CHK2 inhibitor, showing promise for anticancer applications [1].

CUHK242 is a bacterial transcription inhibitor that exhibits antimicrobial activity against Staphylococcus aureus (Staphylococcus aureus). It inhibits RNA synthesis within cells, consequently reducing protein synthesis. For the Bacillus subtilis strain BS2019 (B. subtilis), the minimum inhibitory concentration (MIC) of CUHK242 is reported to be 2 μg/mL.

L-Ornithine hydrochloride ((S)-2,5-Diaminopentanoic acid) has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

Fenoldopam mesylate (Corlopam mesylate) is a selective dopamine-1 receptor (DA1) agonist with natriuretic/diuretic properties. It lowers blood pressure through arteriolar vasodilation.

Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.

Prexasertib (LY2606368) is a selective checkpoint kinase 1 (CHK1) inhibitor (Ki 0.9 nM, IC50<1 nM). Prexasertib causes double-stranded DNA breaks and replication mutations, leading to apoptosis. Prexasertib has antitumor activity.

G-418 disulfate (Geneticin sulfate) is an aminoglycoside antibiotic that selectively inhibits eukaryotic protein synthesis by blocking peptide chain elongation.

Pancreatic Polypeptide, rat acetate is an agonist of NPY receptor, with high affinity at NPYR4.

ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM).

CCT241533 is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM).

CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity.

SLP9101555 is a potent and selective sphingosine kinase 2 (SphK2) inhibitor with a Ki of 90 nM.SLP9101555 has a high affinity for SphK2, which is 200-fold higher than that of SphK1.SLP9101555 dramatically reduces extracellular S1P sphingosine 1-phosphate (S1P) levels.

K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 µM and Ki of 6.4 µM. K145 hydrochloride can induce apoptosis and has strong antitumor activity.

Tenofovir hydrate (GS 1278 hydrate) is a nucleotide reverse transcriptase inhibitor with antiviral activity, inhibits EBV replication, and is used in the study of HIV and HBV.

L-Glutamic acid is an excitatory amino acid neurotransmitter and a Glutamic acid receptor agonist, including metabolic glutamic acid receptor (mGluR), AMPA receptor, NMDA receptor and KA receptor. L-Glutamic acid has an excitatory effect on the process of DA release from dopaminergic nerve endings. L-Glutamic acid can be used in the research of neurological diseases. L-Glutamic acid acts on ionic and metabolic Glutamic acid receptors.

CCT241533 hydrochloride is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM).

K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity. K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM.

M443 is a potent small molecule inhibitor of MRK that inhibits radiation-induced activation of p38 and Chk2 and can be used in cancer research.

VER-00158411 is a checkpoint kinase 1 and CHK2 inhibitor [IC50: 4.4 nM and 4.5 nM, respectively].

BML-277 (C 3742) is a selective checkpoint kinase 2 (Chk2) inhibitor.